Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iparomlimab + tuvonralimab + olaparib + paclitaxel
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This investigational combination therapy consists of QL1706 (a bifunctional MabPair containing the anti-PD-1 antibody iparomlimab and the anti-CTLA-4 antibody tuvonralimab), the PARP inhibitor olaparib, and the microtubule-stabilizing agent paclitaxel. It is currently being evaluated in a Phase II clinical trial (NCT07187674) sponsored by Harbin Medical University as a neoadjuvant treatment for patients with early high-risk, homologous recombination deficiency (HRD)-positive triple-negative breast cancer (TNBC). The regimen leverages the synergistic effects of dual immune checkpoint blockade, synthetic lethality induced by PARP inhibition in HRD-positive cells, and the cytotoxic effects of microtubule disruption. QL1706 is developed by Qilu Pharmaceutical and provides a fixed-ratio delivery of PD-1 and CTLA-4 inhibition.
- Other names
- QL1706 plus olaparib and paclitaxelQL-1706 plus olaparib and paclitaxelQL 1706 plus olaparib and paclitaxeliparomlimab + tuvonralimab + olaparib + paclitaxel-Harbin Medical University-triple-negative breast cancer
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TUBB (Tubulin (alpha and beta subunits))PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on iparomlimab + tuvonralimab + olaparib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iparomlimab + tuvonralimab + olaparib + paclitaxel.